Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Asahi Kasei Pharma
Deal Size : $163.5 million
Deal Type : Licensing Agreement
Asahi Kasei Signs Anti-CX3CR1 Antibody License Agreement for Global Reach
Details : Under the licensing agreement, Asahi Kasei Pharma has acquired worldwide exclusive rights to develop and commercialize PFKR an anti-CX3CR1 antibody from Chiome.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 20, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Asahi Kasei Pharma
Deal Size : $163.5 million
Deal Type : Licensing Agreement